International Journal of Clinical Biochemistry and Research

Print ISSN: 2394-6369

Online ISSN: 2394-6377

CODEN : IJCBK6

International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 542

PDF Downloaded: 292


Get Permission Singh, Gurada, Mahendru, Kashyap, Bhanu, Sharma, and Kaushik: The Vax effect: Role of global vaccination initiatives in pandemic control and impact in Dehradun during COVID-19


Introduction

The eradication of the SARS-CoV-2 beta corona virus, which belongs to the subgenus Sarbeco virus, was one of the most difficult challenges during the third wave. The genetic material of a virus, known as RNA, is continually changing, leading to the generation of new varieties, or strains. This virus is not new to the Earth, but it is new to mankind. Because of the rapid spread and rising number of corona virus disease 19 (Covid-19) cases caused by a new corona virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), rapid and accurate virus and/or disease detection is becoming increasingly important in order to control the sources of infection and assist patients in preventing illness progression.1 According to one study,2 the symptoms of SARS-CoV-2 were fever (59.1%), coughing (55.9%), and asymptomatic (19.3%). SARS-CoV-2 has been labelled a pandemic because the new corona virus has spread around the world as an extremely hazardous illness.3

The use of nucleic acid testing or clinical characteristics of infected persons as the gold standard for determining a definitive diagnosis of Covid-19 patients has proven difficult. For accurate sickness diagnosis and management, newer molecular instruments and processes are being applied. The detection of SARS-CoV-2 virus by RT-PCR is significantly more sensitive than normal culture methods; it has a shorter turnaround time and advantages over real-time RT-PCR.4, 5 A rapid turnaround time also contributed in the correct containment of this highly contagious virus in the general population during the Covid-19 epidemic. Real-time PCR is commonly employed for diagnosis, and it is unclear whether the semi-quantitative capability of this method, which determines viral load using cycle threshold (Ct) values, may be used. Every government was hunting for vaccinations to protect their citizens, either by creating them or importing them from other countries. Vaccines look to be a game-changing technology, so it's critical to understand their efficacy and safety.6, 7 A recent case study was carried out to evaluate vaccination status, which covers the relationship of numerous indicators with regard to SARS-CoV-2Virus and its Clinical importance to investigate its epidemiology.8, 9 Inoculation of respiratory infections in humans by air media is crucial to determining the advantages of immunizations, and large-scale surveys are required.

Materials and Methods

In this investigation, a total of 100 cases exhibiting symptoms of SARS-CoV-2 (covid-19)-like sickness and meeting the criterion of additional symptoms as described by the National Centre for Disease Control, New Delhi, India, were considered. The samples were gathered from various sites within the Dehradun district between September and December 2021. DNA Labs- A Centre for Applied Science (DLCAS) in Dehradun, Uttarakhand, performed the whole SARS-CoV-2 viral genetic profiling. The Covi Path Covid-19 RT-PCR Amplification kit was used to extract the RNA. The Silica Column extraction method was used, as well as a fully automated Insta N Mag-32, Nucleic Acid Extractor, and HiGenoMB was used. The extracted RNA Template was used for Real Time PCR amplification of SARS-CoV-2 probable cases. Master Mix was infected with the SARS-CoV-2 virus for all samples. The Spike protein (S) is encoded by 3831 base pairs of SARS-CoV-2 RNA and determines which type of cell the virus will infect.10, 11 Qiagen's Rotor gene Q Multiplex Real time PCR machine was used for amplification. All requested patients' vaccination status was documented in accordance with ICMR criteria, and data was compiled based on the presence or absence of Ct values, or viral loads indicated by Ct value, and clinical outcomes. Furthermore, a comprehensive overview was conducted to assess the vaccination rate updates in the Dehradun district and other districts within Uttarakhand, considering factors related to both vaccine hesitancy and vaccine acceptance.

Result

The vast majority of new infections were caused by unvaccinated individuals, and 90% of confirmed positive cases were asymptomatic. Due to the 'de-coupling' of SARS CoV-2 infection from moderate to severe disease, the usage of hospital beds, oxygen beds, and intensive care units (ICUs) has remained modest. Subclinical disease emerged in people who had been fully immunized. Other aspects of the health-care system provide some confidence. Although there were Covid-19 cases admitted to hospitals, a significant proportion of Covid-19 dedicated beds remained empty. Then there was the case when the majority of those hospitalized for suspected Covid-19 were discovered to have other health issues. They were hospitalized for causes other than SARS Covid-19 symptoms. In the third wave, almost all persons who were either unvaccinated or had previous health issues were seen to be hospitalized to the ICU after testing positive for Covid-19.

Figure 1

Positive cases with Open Reading Frame(ORF) and Nucleocapsid(N) Gene Positive value and Negative cases

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/635181e4-64c7-4af9-b304-89bbf55a9330/image/675d04fa-1c2c-4944-ab7a-09779287cc17-uimage.png

Out of a total of 100 cases (68%), 54 were positive for Covid-19 and 46 were negative, with 6 cases being vacinated yet positive and 22 vaccinated patients being negative for Covid-19 patients were unvaccinated and positive for Covid-19, while 7 patients were unvaccinated and negative. There were 13 vaccinated but positive instances, and 87 vaccinated but negative ones. Males outnumbered females (59) by a large margin. The gender distribution of patients in the current study revealed a male preponderance over females. Many research12, 13 reported a comparable preponderance of males over girls as 58%, 62%, respectively. A few studies conducted in India also shown that males were more likely to be infected with Covid-19 than females.14, 15, 16 Males are also more likely than females to be infected with Covid-19.17, 18, 19 It has been proposed that females are less susceptible to viral infections due to natural protection from the X chromosome and sex hormones.20

Figure 2

Covid-19 cases in vaccinated and non-vaccinated patients along with male and female proportion

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/635181e4-64c7-4af9-b304-89bbf55a9330/image/ee316bcd-caa1-4b27-8d23-160fa5e04736-uimage.png

The percentages and patterns of positive cases and admitted patients for covid-19 were radically different when we compared the third wave in Dehradun to the first and second waves. According to the findings, the majority of those who tested positive were unvaccinated, while there were rare cases when vaccinated people tested positive, which was not as harmful as not having active protection due to vaccination. Because no vaccine is 100% effective, "breakthrough infections" were always a possibility. The symptoms are frequently mild, which admits the phenomena of "breakthrough infections" caused by vaccination ineffectiveness, as demonstrated by the yellow fever vaccine's 98% effectiveness. However, this still means that 2% of people will become sick.21, 22, 23, 24

The current study examines the gender distribution of Covid-19 cases, demonstrating a significant male preponderance over girls, a tendency supported by earlier research. It consistently shows that males have a higher incidence of Covid-19 than females. The study also looks at the influence of vaccination, finding that the majority of positive cases in the third wave in Dehradun were among unvaccinated people.

Table 1

A summary of prominent Covid-19 vaccines, showcasing their varying efficacy results from Phase III clinical trials conducted across different regions, presented in a tabular format with references

Vaccine

Type

Developer

Phase III Efficacy (%)

Geographical Areas

References

Oxford-AstraZeneca (AZD1222)

Viral Vector (ChAdOx1-5)

University of Oxford, AstraZeneca

70.4 (Overall, 95% CI 54.8–80.6) <br> 62.1 (2-standard dose, 95% CI 41.0–75.7) <br> 90.0 (Low dose + standard dose, 95% CI 67.4–97.0)

UK

(Voysey et al., 2021)25

Johnson & Johnson (Ad26.COV2.S)

Viral Vector (Ad26)

Johnson and Johnson

66.9 (95% CI 59.0–73.4) <br> 76.3 (≥60 years old, 95% CI, 61.6–86.0)

USA

(Tehrani and Sajadi, 2021)26

Moderna (mRNA-1273)

mRNA

Moderna and NIAID

94.1 (95% CI 89.3–96.8)

USA

(Baden et al., 2021)27

Pfizer-BioNTech (BNT162b2)

mRNA

Pfizer and BioNTech

94.6 (95% CI 89.9–97.3)

USA, Germany

(Iannone et al., 2020)28

Gamaleya (Sputnik V)

Viral Vector (rAd26+rAd5)

Gamaleya Research Institute, Russia

91.6 (95% CI 85.6–95.2)

Russia

(Logunov et al., 2021)29

CanSino (Convidecia)

Recombinant Adenovirus (Ad5)

Beijing Institute of Biotech, CanSino Biological

65.7 (As per company claim)

China

(Zhu, F et al., 2022)30

Novavax (NVX-CoV2373)

Protein Subunit

Novavax (Gaithersburg, USA)

89.7 (95% CI 80.2–94.6)

USA

(lan J et al., 2021, polack et al., 2020)31, 32 (39,40)

Covaxin

Inactivated Virus

Bharat Biotech

77.8 (95% CI 65.2–86.4)

India

(Ella et al., 2021)32

Sinovac-CoronaVac

Inactivated Virus

Sinovac Biotech

Varied

Multiple countries including Brazil, Turkey, Indonesia

(Al Kaabi et al., 2021)33

Sinopharm-BBIBP-CorV

Inactivated Virus

China National Pharmaceutical Group (Sinopharm)

Varied

Multiple countries including UAE, Bahrain, Egypt

(Wu, Y et al., 2021)34

Aside from the study, an evaluation was conducted to explore Hesitancy against the newly produced COVID-19 vaccinations is a global occurrence. Although, for much clearer data, vaccination/infection history would necessitate substantial investigation, data collecting, and analysis. According to available literature, vaccine reluctance varies greatly between countries.35, 36, 37, 38 Vaccine hesitation was defined by the WHO as a "delay in acceptance or refusal of vaccination despite the availability of vaccination services." Various survey items deployed to investigate questions pertaining to COVID-19 vaccine hesitancy, such as whether people are willing to be vaccinated, the reasons why they are willing or unwilling to do so, and the most trusted sources of information in their decision-making, across 13 studies conducted in Africa, South Asia, Latin America, Russia, and the United States. Overall, they discovered that the average acceptance rate across all studies in low- and middle-income countries (LMICs) was 80.3%, with the lowest acceptance rates in Burkina Faso.37, 38, 39, 40 When we see the data 10 July to 6 August 2023), approximately 1.5 million new COVID-19 cases and over 2500 deaths were reported globally, and an increase of 80% and a drop of 57%, respectively, While five WHO areas reported decreases in both the number of cases and deaths, the Western Pacific Region reported an increase in both cases and deaths.41, 42, 43, 44, 45

When we talk about Uttarakhand Total 91, 18, 676 - 80.00% of citizens received at-least one dose of vaccine in Uttarakhand, about 87,33,083 - 76.61% fully vaccinated.42, 46 The table provides the data of vaccination till 2 Nov 2023 of covid-19 showing the non-hesitancy (Figure 3) of people of districts of Uttrakhand and Dehradun and other districts.

Figure 3

Vaccination data of Districts of Uttarakhand including Dehradun

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/635181e4-64c7-4af9-b304-89bbf55a9330/image/c42a1a72-26ab-428f-9c10-254131fe09f1-uimage.png

Like the nationwide approach to COVID-19 vaccination in India, the immunization process in Uttarakhand has unfolded in several stages. Initially, healthcare workers, frontline personnel, and senior citizens received primary focus for vaccination. Over time, the eligibility criteria for vaccination may have evolved to encompass various age groups and other specific categories. Vaccination centers were established in multiple government and private healthcare facilities throughout Uttarakhand. Awareness campaigns aimed at promoting vaccination and educating the public on its significance have been conducted by the state government and health authorities.41, 42, 43

Discussion

The study emphasizes that even with immunizations a small number of people may still become infected with the virus. The bulk of the top Covid-19 vaccines achieved efficacy against symptomatic infection of more than 90% in phase 3 trials. Real-world efficacy studies in the United Kingdom, Israel, and Canada show that vaccine efficacy is slightly lower outside of the trial setting, most likely due to the spread of the more vaccine-resistant Delta variant. Estimates suggest protection against symptomatic illness at 60-90 percent, depending on the vaccination. Only a small percentage of fully vaccinated patients who test positive for Covid-19 die.47, 48, 49, 50 PHE's real-world studies show that the BioNTech/Pfizer vaccination is still 96% effective against hospitalization, whereas the Oxford/AstraZeneca vaccine is 92% effective. However, Natalie Dean, a biostatistics professor at Emory University in Atlanta, stressed that these findings were based on averages and that efficacy was reliant on individuals' existing risk profiles. Individuals with impaired immune systems may only create enough antibodies to resist a 100-fold dilution. In contrast, healthy young adults may have enough for a 10,000-fold dilution and are "likely impervious" to infection.51, 52 If scientists could establish a happy medium between the two extremes, vaccine manufacturers would be able to update vaccines more quickly for new strains, and policymakers would be able to better determine who needed booster doses the most. Due to the urgent global need to combat the pandemic, COVID-19 vaccinations were created and launched in record time. The Pfizer-BioNTech vaccine was the first COVID-19 vaccine to be approved for emergency use. On December 2, 2020, the United Kingdom authorized its use for emergency purposes.53, 54 Other vaccines, including the Moderna vaccine, the AstraZeneca-Oxford vaccine, and the Johnson & Johnson vaccine, were also approved for emergency use in a number of nations in late 2020 and early 2021. The precise dates of permission vary depending on the country and regulatory body. 55 On January 16, 2021, India initiated its Covid-19 vaccine campaign. Initially, the nation approved two vaccines for emergency use. Oxford-AstraZeneca's Covishield AstraZeneca licensed the Serum Institute of India (SII) to manufacture the vaccine. Covishield was one of the first vaccinations used in India's vaccination campaign. Covaxin (Bharat Biotech Vaccine) is an inactivated viral vaccine developed in partnership with the Indian Council of Medical Research (ICMR) by Bharat Biotech. It was approved for emergency use in India and has been used in the country's vaccination efforts. As the immunization campaign progressed, India approved more vaccines for emergency use, although Covishield and Covaxin were the initial vaccinations introduced in the country's Covid-19 programmed.56, 53, 55 Although the Omicron variant appears to induce lesser symptoms than prior variants in persons who have been completely vaccinated and boosted, we do not know if another variant with more severe symptoms and the same level of immune escape will emerge. SARS-CoV-2 may also become endemic and continue to circulate in the community for the foreseeable future.56, 57 COVID-19 vaccination hesitancy can stem from a range of factors. Safety concerns and apprehensions about potential side effects may have deterred some individuals. Additionally, distrust in the vaccine development process or pharmaceutical companies can be a driver of hesitancy, and the proliferation of misinformation and vaccine-related myths may have sowed doubts about vaccination. Needle phobia is a significant impediment for certain people, while others may harbor the belief that natural infection offers superior immunity compared to vaccination. Negative encounters with vaccines in the past can further contribute to vaccine hesitancy, as can concerns regarding the rapid pace of vaccine development and approval processes. In regions where COVID-19 cases have remained relatively low, a sense of complacency may have developed among certain individuals, leading to reduced urgency in pursuing vaccination. Meanwhile, a wait-and-see approach may be favored by some, as they prefer to observe how the vaccine performs in others before opting for vaccination themselves. Additionally, cultural or religious convictions can significantly impact vaccination decisions. Limited access to vaccination centers and logistical difficulties can pose substantial barriers to getting vaccinated. Concerns about vaccination may also arise among individuals with specific health conditions or allergies. Lastly, political or ideological beliefs may play a role in influencing vaccine hesitancy. Crucial for public health initiatives is the need to confront these apprehensions through educational outreach, transparent communication, and the widespread dissemination of precise information. This approach fosters vaccine acceptance and contributes to the containment of COVID-19 transmission.50, 58

Conclusion

Transmission rate of omicron was limited in third wave because Covid-19 Vaccines was Master key to prevent infection and reduce transmission. In order to maintain the control over omicron and other virulence effect of Covid-19 vaccinated people also need to continue social distancing and keep wearing a mask in public places. It's good thing to see the population of Dehradun were much more conscious of wearing masks more carefully and acquired in the life style as basic requirements.59 In a nutshell the adoption rate of the Covid-19 vaccine and vaccination intention were unsatisfactory for achieving herd immunity. It is critical for governments, public health professionals, and economic and social groups to adopt a strategy to increase vaccination acceptance, particularly among the working population.36, 60 This Covid-19 pandemic has changed the way we live, and it will continue to shape our future life. People are conceptually more willing to be vaccinated and wear masks in daily life and remote working and learning will probably become a feasible option in the future. Whether or not we will encounter another pandemic this century is unknown but, just in case, we will need to be prepared mentally, scientifically, and infrastructuraly.35, 36, 60, 46, 49, 50

Source of Funding

None.

Conflict of Interest

None.

References

1 

M Ciotti M Ciccozzi A Terrinoni WC Jiang CB Wang S Bernardini The COVID-19 pandemicCrit Rev Clin Lab Sci202057636588

2 

JR Hageman Current Status of the COVID-19 Pandemic, Influenza and COVID-19 Together, and COVID-19 Viral VariantsPediatr Ann202049114489

3 

S Platto T Xue E Carafoli COVID19: an announced pandemicCell Death Dis202011979910.1038/s41419-020-02995-9

4 

N Rifai MA Gillette SA Carr Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNat Biotechnol200624897183

5 

K Mayer-Blackwell S Koshlan L Cohen-Lavi JC Crawford A Souquette JA Gaevert TCR meta-clonotypes for biomarker discovery with tcrdist3: identification of public, HLA-restricted SARS-CoV-2 associated TCR featuresbioRxiv20211042426010.1101/2020.12.24.424260

6 

J Huggett K Dheda S Bustin A Zumla Real-time RT-PCR normalisation; strategies and considerationsGenes Immun20056427984

7 

UE Gibson CA Heid PM Williams A novel method for real time quantitative RT-PCRGenome Res19966109951001

8 

TL Lash TJ VanderWeele S Haneuse KJ Rothman Modern epidemiologyVol. 3Wolters KluwerPhiladelphia2008

9 

KJ Rothman Epidemiology: an introductionOxford University PressUnited Kingdom2012

10 

E Pujadas M Beaumont H Shah N Schrode N Francoeur S Shroff Molecular profiling of coronavirus disease 2019 (COVID-19) autopsies uncovers novel disease mechanismsAm J Pathol202119112206471

11 

S Belouzard JK Millet BN Licitra GR Whittaker Mechanisms of coronavirus cell entry mediated by the viral spike proteinViruses201246101133

12 

WJ Guan ZY Ni Y Hu WH Liang CQ Ou JX He Clinical Characteristics of Coronavirus Disease 2019 in ChinaN Engl J Med2020382170820

13 

D Wang B Hu C Hu F Zhu X Liu J Zhang Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, ChinaJAMA20203231110619

14 

S Richardson JS Hirsch M Narasimhan JM Crawford T Mcginn KW Davidson Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA20203232020529

15 

G Grasselli A Zangrillo A Zanella M Antonelli L Cabrini A Castelli Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, ItalyJAMA202032316157481

16 

M Colaneri P Sacchi V Zuccaro S Biscarini M Sachs S Roda Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020Euro Surveill20202516200046010.2807/1560-7917.ES.2020.25.16.2000460

17 

S Budhiraja A Soni V Jha A Indrayan A Dewan O Singh Clinical profile of first 1000 COVID-19 cases admitted at tertiary care hospitals and the correlates of their mortality: An Indian experiencemedRxiv202010.1101/2020.11.16.20232223

18 

A Mohan P Tiwari S Bhatnagar A Patel A Maurya L Dar Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north IndiaIndian J Med Res20201521 & 2619

19 

H Kaur M Singh K Kaur A Kaur R Singh N Patel Clinical Profile and Outcomes of Patients Admitted with COVID-19 Infection –Report from a Tertiary HospitalJ Med Sci Clin Res2021919410.18535/jmscr/v9i1.37

20 

A Badawi SG Ryoo Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV):A systematic review and meta-analysisInt J Infect Dis20164933

21 

R Channappanavar C Fett M Mack PPT Eyck DK Meyerholz S Perlman Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus InfectionJ Immunol201819810404653

22 

ES Jentes G Poumerol MD Gershman DR Hill J Lemarchand RF Lewis The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow FeverLancet Infect Dis201111862232

23 

ME Wilson LH Chen ED Barnett Yellow fever immunizations: indications and risksCurr Infect Dis Rep2004613442

24 

AD Barrett TP Monath V Barban M Niedrig DE Teuwen 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005Vaccine20052515275865

25 

NA Kaabi Y Zhang S Xia Y Yang MMA Qahtani N Abdulrazzaq Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trialJAMA202132613545

26 

R Ella KM Vadrevu H Jogdand S Prasad S Reddy V Sarangi Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trialLancet Infect Dis202121563746

27 

ZR Tehrani MM Sajadi Single-dose Ad26.COV2.S vaccine-room for improvementJAMA Netw Open2021411e213301210.1001/jamanetworkopen.2021.33012

28 

FP Polack SJ Thomas N Kitchin J Absalon A Gurtman S Lockhart Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccineN Engl J Med202038327260315

29 

F Zhu P Jin T Zhu W Wang H Ye H Pan Safety and immunogenicity of a recombinant adenovirus type-5-vectored corona virus disease 2019 (COVID-19) vaccine with a homologous prime-boost regimen in healthy participants aged≥ 6 years: a randomized, double-blind, placebo-controlled, phase 2b trialClin Infect Dis202275178391

30 

DY Logunov IV Dolzhikova DV Shcheblyakov AI Tukhvatulin OV Zubkova AS Dzharullaeva Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in RussiaLancet20213971027567181

31 

M Voysey SAC Clemens SA Madhi LY Weckx PM Folegatti PK Aley Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (Azd1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKLancet20213971026999111

32 

Y Wu X Huang L Yuan S Wang Y Zhang H Xiong A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamstersSci Transl Med2021136061143

33 

LR Baden M El Sahly B Essink K Kotloff S Frey R Novak Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineN Engl J Med2021384540316

34 

M Iannone A Janowska G Tonini G Davini V Dini Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativaClin Dermatol20213947012

35 

SJ Thomas ED Moreira N Kitchin J Absalon A Gurtman S Lockhart Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 monthsN Engl J Med201938519176173

36 

Y Goldberg M Mandel YM Bar-On O Bodenheimer L Freedman EJ Haas Waning immunity after the BNT162b2 vaccine in IsraelN Engl J Med202138524e85

37 

JB Soriano S Murthy JC Marshall P Relan JV Diaz A clinical case definition of post-COVID-19 condition by a Delphi consensusLancet Infect Dis20222241027

38 

S Houben B Bonnechère The impact of COVID-19 infection on cognitive function and the implication for rehabilitation: a systematic review and meta-analysisInt J Environ Res Public Health202219137748

39 

E Dirican T Bal COVID-19 disease severity to predict persistent symptoms: a systematic review and meta-analysisPrim Health Care Res Dev202223e69

40 

S Lopez-Leon T Wegman-Ostrosky C Perelman R Sepulveda PA Rebolledo A Cuapio More than 50 long-term effects of COVID-19: a systematic review and meta-analysismedRxiv2021112125061710.1101/2021.01.27.21250617

41 

HE Davis L Mccorkell JM Vogel EJ Topol Long COVID: major findings, mechanisms and recommendationsNat Rev Microbiol20232113346

44 

JJ Lau SMS Cheng K Leung CK Lee A Hachim LCH Tsang Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive populationNat Med202329234857

45 

00:00) (The Government of the Hong Kong Special Administrative RegionStatistics on 5th Wave of COVID-192021

46 

M Morvan AL Jacomo C Souque MJ Wade T Hoffmann K Pouwels An analysis of 45 large-scale wastewater sites in England to estimate SARS-CoV-2 community prevalenceNat Commun20221314313

47 

World Health Organization. Novel Coronavirus (2019-nCoV), Situation Report - 1https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf

48 

CEPI to fund three programmes to develop vaccines against the novel coronavirus, nCoV-2019https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/

49 

F Amman R Markt L Endler S Hupfauf B Agerer A Schedl Viral variant-resolved wastewater surveillance of SARS-CoV-2 at national scaleNat Biotechnol20224012181422

50 

CKP Mok CA Cohen SMS Cheng C Chen KO Kwok K Yiu Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong KongRespirology202227430110

51 

DD Chaplin Overview of the immune responseJ Allergy Clin Immunol20101252323

52 

H Goodarzi J Trowbridge RL Gallo Innate immunity: a cutaneous perspectiveClin Rev Allergy Immunol2007332432

53 

R Patel M Kaki VS Potluri P Kahar D Khanna A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & JohnsonHum Vaccin Immunother20221812002083

54 

J Aldali SA Meo T Al-Khlaiwi Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional StudyVaccines (Basel)2023112231

55 

H Lotfi MG Mazar NM Ei M Fahim NS Yazdi Vaccination is the most effective and best way to avoid the disease of COVID-19Immun Inflamm Dis2023118e946

56 

WY Chi YD Li HC Huang TEH Chan COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protectionJ Biomed Sci 202229182

57 

H Allen E Tessier C Turner C Anderson P Blomquist D Simons Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, EnglandEpidemiol Infect2023151e58

58 

J Bullock JE Lane FL Shults What causes COVID-19 vaccine hesitancy? Ignorance and the lack of bliss in the United KingdomHumanit Soc Sci Commun202298710.1057/s41599-022-01092-w

59 

L Hong Z Jin K Xu COVID-19 vaccine uptake and vaccine hesitancy in rural-to-urban migrant workers at the first round of COVID-19 vaccination in ChinaBMC Public Health202323139139

60 

Coronavirus disease (COVID-19) Weekly Epidemiological Updates and Monthly Operational Updates2023https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Original Article


Article page

320-326


Authors Details

Ankita Singh*, Nivedita Chetan Gurada, Nidhi Mahendru, Abhijeet Kashyap, Sourabh Bhanu, Narotam Sharma, Ritu Kaushik


Article History

Received : 22-08-2023

Accepted : 04-12-2023


Article Metrics


View Article As

 


Downlaod Files